Vor Biopharma Inc. (VOR) — 10-K Filings
All 10-K filings from Vor Biopharma Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Vor Biopharma Pivots to Autoimmune with Telitacicept, Initiates Global Phase 3 Trials
— Mar 30, 2026 Risk: high
Vor Biopharma Inc. (VOR) reported significant strategic shifts in its 2025 fiscal year, in-licensing telitacicept from RemeGen Co., Ltd. in June 2025 for exclus -
Vor Biopharma Files 2024 10-K
— Mar 20, 2025 Risk: medium
Vor Biopharma Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological products, is -
Vor Biopharma Inc. Files 2023 Annual Report on Form 10-K
— Mar 20, 2024 Risk: medium
Vor Biopharma Inc. (VOR) filed a Annual Report (10-K) with the SEC on March 20, 2024. Vor Biopharma Inc. filed its 2023 Form 10-K on March 20, 2024. The filing
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX